The European Medicines Agency and national regulators in the European Union member states are proposing to relax procedures regarding the protection of pharmaceutical data in order to put more information into the public domain.
Silence Therapeutics Plc has outlined plans for the early clinical development of its two lead cancer products following the successful completion of a share offering that raised £5.5 million, net of expenses, from existing and new shareholders.
Roche and Bristol-Myers Squibb Company have announced plans to investigate a combination of vemurafenib and ipilimumab in patients with BRAF-mutated metastatic melanoma. The two agents target the disease in different ways.
A spin-out of NV Philips Electronics that is developing brain stimulation technology has raised €13 million in a Series A financing round from Wellington Partners, Edmond de Rothschild Investment Partners and Life Sciences Partners.
Evotec AG is paying €10.25 million in cash upfront to acquire the US compound management business of Galápagos NV in a move that will substantially increase its ability to help third parties develop and manage their compound libraries.
TiGenix NV of Belgium has raised €15.2 million in a rights issue, putting the finishing touches on a merger with Cellerix SA of Spain to create a new, larger company focused on cell-based therapeutics. The issue was fully subscribed.
Shield Therapeutics, a Switzerland-based speciality pharmaceutical company, has raised €8.2 million in a Series A financing round from Inventages Venture Capital in order to help fund the late-stage development of a product for anaemia.
Heptares Therapeutics Ltd has reached an agreement with AstraZeneca Plc to explore a number of G-protein coupled receptors (GPCR) as possible targets for new drugs – its third discovery partnership since April.
Paion AG is set to receive $3 million from Ono Pharmaceutical Co Ltd of Japan for the start of a Japanese Phase 2 study of its short-acting sedative, remimazolam. The payment brings total milestones for the project up to $4 million.
MediGene AG has entered into a collaboration with the Johns Hopkins University in Baltimore, US to test candidate vaccines against the human papillomaviruses using an adeno-associated virus platform. Financial terms were not disclosed.